Lyra Therapeutics Inc.

NASDAQ: LYRA · Real-Time Price · USD
7.06
-0.04 (-0.56%)
At close: Aug 15, 2025, 3:59 PM
6.87
-2.69%
After-hours: Aug 15, 2025, 06:51 PM EDT

Lyra Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
183K 183K 209K 195K 598K 532K 146K 544K 458K 410K 11K 359K 407K 5.37M 271K 14K n/a n/a
Cost of Revenue
200K n/a n/a 39K 145K 136K 85K 12.37M 10.8M n/a 222K n/a 300K 280K 14K 6.38M 300K 70K
Gross Profit
-17K 183K 209K 195K -12.67M 396K 61K -11.82M -10.34M 410K -211K 359K 107K 5.09M 257K -6.36M -300K -70K
Operating Income
-8.43M -8.84M -11.41M -12.44M -48.97M -23.52M -16.48M -16.83M -16.5M -17.31M -15.15M -14.83M -14.52M -7.03M -13.64M -11.08M -11.06M -7.83M
Interest Income
410K 298K 435K 576K 855K 1.09M 1.34M 1.19M 897K 1.07M 933K 60K 34K 14K 21K 26K 26K 29K
Pretax Income
-7.43M -8.54M -10.97M -11.87M -48.12M -22.44M -15.14M -15.63M -15.61M -16.24M -14.22M -14.77M -14.48M -7.01M -13.62M -11.05M -11.04M -7.8M
Net Income
-7.44M -8.55M -10.98M -11.87M -48.13M -22.45M -15.16M -15.65M -15.62M -16.25M -14.23M -14.77M -14.42M -7M -13.34M -11.05M -11.04M -7.8M
Selling & General & Admin
3.3M 3.26M 3.61M 3.93M 5.14M 5.82M 4.36M 5M 4.57M 5.13M 4.4M 5.14M 4.13M 3.89M 3.57M 4.02M 3.56M 3.06M
Research & Development
5.11M 4.88M 6.36M 5.9M 13.26M 18.1M 12.18M 12.37M 10.8M 12.6M 9.45M 10.05M 10.79M 8.51M 10.34M 7.08M 7.5M 4.77M
Other Expenses
n/a 885K 1.64M 2.8M 17.91M n/a n/a n/a 1.59M n/a 1.32M n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
8.41M 9.02M 11.62M 12.64M 36.31M 23.92M 16.54M 17.37M 15.37M 17.72M 13.85M 15.19M 14.93M 12.39M 13.91M 11.1M 11.06M 7.83M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
8.61M 9.02M 11.62M 12.64M 49.57M 24.06M 16.62M 17.37M 15.37M 17.72M 13.85M 15.19M 14.93M 12.39M 13.91M 11.1M 11.06M 7.83M
Income Tax Expense
2K 4K 6K 7K 12K 14K 17K -16K 12K 14K 13K n/a -68K -14K -278K -26K -26K -29K
Shares Outstanding (Basic)
1.35M 65.76M 65.11M 65.46M 65.46M 64.01M 61.24M 56.95M 43.68M 36.83M 31.71M 36.83M 33.95M 13.01M 12.97M 13M 12.99M 12.95M
Shares Outstanding (Diluted)
1.35M 65.76M 65.11M 65.46M 65.46M 64.01M 61.53M 56.95M 43.68M 36.83M 31.83M 36.83M 33.95M 13.01M 13M 13M 12.99M 12.95M
EPS (Basic)
-5.51 -0.13 -0.17 -0.18 -0.73 -0.35 -0.25 -0.27 -0.36 -0.44 -0.45 -0.4 -0.42 -0.92 -1.05 -0.85 -0.85 -0.6
EPS (Diluted)
-5.51 -0.13 -0.17 -0.18 -0.73 -0.35 -0.25 -0.27 -0.36 -0.44 -0.45 -0.4 -0.42 -0.92 -1.05 -0.85 -0.85 -0.6
EBITDA
-7.24M -8.41M -9.62M -9.6M -17.66M -23.39M -16.39M -16.83M -14.91M -17.03M -13.62M -14.55M -14.11M -11.64M -13.36M -10.73M -10.76M -7.76M
EBIT
-7.43M -8.54M -9.77M -9.64M -17.8M -23.52M -16.48M -16.83M -14.91M -17.31M -13.84M -14.83M -14.4M -11.93M -13.64M -11.08M -11.06M -7.83M
Depreciation & Amortization
200K 128K 151K 39K 145K 136K 85K -68K -23K 284K 222K 279K 300K 280K 278K 400K 300K 70K